Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 11/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241210 | 0.90 | HCRTR1 (0.37) | HCRTR2HCRTR1 | |
| SCHEMBL10239726 | 0.89 | HCRTR1 (0.36) | HCRTR2HCRTR1CYP2C19 | |
| SCHEMBL10241695 | 0.88 | HCRTR2 (0.40) | HCRTR2HCRTR1CYP2C8CYP2C19USP30 | |
| SCHEMBL10239735 | 0.88 | HCRTR2 (0.41) | HCRTR2HCRTR1CYP2C8CYP2C19USP30 | |
| SCHEMBL10241669 | 0.84 | HCRTR1 (0.37) | HCRTR2HCRTR1 | |
| SCHEMBL10240880 | 0.83 | POLB (0.31) | — | |
| SCHEMBL10189120 | 0.80 | HCRTR2 (0.59) | HCRTR2HCRTR1CYP2C8CYP2C19 | |
| SCHEMBL10241215 | 0.78 | HCRTR1 (0.38) | HCRTR2HCRTR1 | |
| SCHEMBL10239736 | 0.78 | HCRTR1 (0.37) | HCRTR2HCRTR1 | |
| SCHEMBL10239732 | 0.78 | HCRTR1 (0.37) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | HCRTR2 1/4885HCRTR1 2/4885CYP2C8 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.